Investing

Astria Therapeutics : ATXS

ATXS

Stock Data

$13.12

$0.03 (0.23%)

Asset Type

Common Stock

Exchange

NASDAQ

Currency

USD

Country

USA

Sector

HEALTHCARE

Industry

BIOTECHNOLOGY

Astria Therapeutics, Inc. is a Boston-based biopharmaceutical firm dedicated to developing treatments for rare and specialized allergic and immunological diseases. Its flagship project, STAR-0215, is a pioneering monoclonal antibody aimed at treating hereditary angioedema, currently in the clinical trial phase. Originally known as Catabasis Pharmaceuticals, Astria rebranded in 2021, continuing its mission since its inception in 2008 to address unmet medical needs in niche disease areas.

All Astria Therapeutics Articles

2 Articles

Trey Thoelcke | Feb 12, 2024 at 8:53 AM EST

Another Huge Buffett Purchase Highlights Recent Insider Buying

Another huge Warren Buffett purchase highlighted the past week's insider buying, and a couple of IPOs also prompted insiders to…

Trey Thoelcke | Dec 31, 2023 at 10:10 AM EST

Here’s What Insiders Are Buying to Wrap Up the Year

As the year wound to a close, the most notable insider buying was focused on biotech stocks, but an oil…